← Leaderboards
Rongshi Li
H. Lee Moffitt Cancer Ctr & Res Inst
$1,004,074
Attributed
$1,004,074
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $366.3K · FY2013–15$500K$375K$250K$125K$0
'13
'14
'15
Funding mix
By agency
NIH$1,004,074 · 1
By mechanism
R01$1,004,074 · 1
Top collaborators
No co-investigators on record.
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- Peter A Kanetsky$11,078,381
- Nagi B Kumar$8,902,562
- Thomas D Bannister$24,896,252
- John L. Cleveland$27,832,236
- Wayne C Guida$1,024,288
Others in their field
Top investigators on “Animal Model”
- David Heimbrook · Leidos Biomedical Research, Inc.$464,525,875
- Dennis R. Burton · Scripps Research Institute$204,129,233
- Joseph E Robertson · Oregon Health & Science University$126,125,279
- Peter Gordon Gillespie · Oregon Health And Science University$105,808,119
- David M Anderson · University Of Washington$102,920,737
- Polly Chang · Sri International$84,271,267
Research focus
Animal ModelApplications GrantsAutoimmune DiseasesBaseBinding (Molecular Function)Binding SitesCancer CellCardiovascular DiseasesCell MotilityCellsChemokineChemokine ReceptorChemotaxisCleaved CellComplexComputer SimulationCrystallographyCxcl12 GeneCxcr4 GeneCxcr4 ReceptorsDesignDiagnosisDisseminated Malignant NeoplasmAffinity
Grant awards (3)
Targeting the CXCL12/CXCR4 Axis toward the Therapy of Metastatic Cancers$310,905
R01 · FY2015 · CA · contact PI
Targeting the CXCL12/CXCR4 Axis toward the Therapy of Metastatic Cancers$326,828
R01 · FY2014 · CA · contact PI
Targeting the CXCL12/CXCR4 Axis towards the Therapy of Metastatic Cancers$366,341
R01 · FY2013 · CA · contact PI